Clinical Trials Logo
  1. Home
  2. Pancreatic Cancer Resectable
  3. NCT04224402

Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.

Pancreatic Cancer Resectable Clinical Trial

Official title:
Phase 2 Trial to Investigate the Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.

Clinical Trial Summary

This prospective and open-label study evaluates the efficacy and safety of mFOLFIRINOX as postoperative chemotherapy in treating Chinese patients with pancreatic cancer after R0/R1 resection.

Clinical Trial Description

The patients will be treated with systemic FOLFIRINOX chemotherapy of adjusted dosage. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04224402
Study type Interventional
Source Sun Yat-sen University
Contact
Status Completed
Phase Phase 2
Start date January 31, 2020
Completion date December 31, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06368063 - The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer Phase 4
Not yet recruiting NCT06375928 - EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial) N/A
Recruiting NCT06388967 - Pancreatic Cancer Detection Consortium
Completed NCT05483257 - Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
Recruiting NCT05287165 - Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms Early Phase 1
Not yet recruiting NCT06287749 - French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
Recruiting NCT03977233 - Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Phase 2
Recruiting NCT04736043 - Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Resected Pancreatic Cancer Using Organoid
Terminated NCT03344172 - Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer Phase 2
Not yet recruiting NCT05479708 - ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Not yet recruiting NCT05637567 - Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head Phase 2
Recruiting NCT05181605 - Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors Phase 2/Phase 3